Final Program
INVITED SPEAKERS
-
Esteban Domingo, PhD
Esteban Domingo, PhD Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Spain
Quasispecies dynamics and antiviral designs
...
Read more
-
Jeffrey Florian, PhD
Jeffrey Florian, PhD US Food and Drug Administration (FDA), USA
Observations from the AIMS database
...
Read more
-
Jeremie Guedj, PhD
Jeremie Guedj, PhD Los Alamos National Laboratory, USA
Viral Dynamics
...
Read more
-
Patrick Harrington, PhD
Patrick Harrington, PhD FDA/CDER, USA
HCV Drug Resistance form Regulatory Perspective (FDA)
...
Read more
-
Katyna Borroto-Esoda, MS
Katyna Borroto-Esoda, MS Scynexis, USA
Mechanism of Action of Cyclophilin-inhibitor Class Compounds
...
Read more
-
Cassandra Jabara, BA
Cassandra Jabara, BA University of North Carolina at Chapel Hill, USA
New Screening Technology - Primer ID Sequencing
...
Read more
-
Ira Jacobson MD
Ira Jacobson MD Cornell University Weill Medical College, New York, USA
The Unfolding Story of DAA combination regimens: How do host factors and viral resistance influence outcomes?
...
Read more
-
Filip Josephson, MD, PhD
Filip Josephson, MD, PhD Swedish Medical Products Agency (MPA), Sweden
HCV Drug Resistance from a Regultory Perspective (EMA)
...
Read more
-
Randall Lanier, PhD
Randall Lanier, PhD Chimerix, Inc, USA
Rational Design of Nucleotides for Intracellular Delivery
...
Read more
-
Stanley M. Lemon, MD
Stanley M. Lemon, MD University of North Carolina (UNC) at Chapel Hill, USA
The role of MIR122 in HCV Pathogenesis
...
Read more
-
Fiona McPhee, D.Phil.
Fiona McPhee, D.Phil. Bristol-Myers Squibb, USA
Resistance profile of NS5A replication complex inhibitor
...
Read more
-
Adrian Ray, PhD
Adrian Ray, PhD Gilead Sciences, USA
Rational design of nucleotide prodrugs for intracellular delivery - new tenofovir prodrug, GS 7340
...
Read more
-
Christoph Sarrazin, MD
Christoph Sarrazin, MD J.W. Goethe University Hospital Frankfurt, Germany
Viral determinants of selection of resistant variants and fate of resistance on the long-term
...
Read more
-
Michael Sofia, PhD
Michael Sofia, PhD Gilead Sciences, USA
Prodrugs of Nucleoside and Nucleotide Analogs for the Treatment of HCV: An Overview of Concepts and Chemistry
...
Read more
-
Andrew Talal, MD, MPH
Andrew Talal, MD, MPH Cornell University, Weill Medical College, USA
Serial Hepatic Sampling during DAA Therapy: Pharmacokinetics, Pharmacodynamics, and Antiviral Resistance
...
Read more
